Xagena.net - Update in Medicine


MHRA [ The Medicines and Healthcare products Regulatory Agency ] ( 9 December 2020 ) has issued updated guidance to COVID-19 vaccination centres about the management of anaphylaxis, following two reports of anaphylaxis and one report of a possible allergic reaction following immunisation.

The MHRA’s updated advice is:

a) Any person with a history of immediate-onset anaphylaxis to a vaccine, medicine or food should not receive the Pfizer / BioNTech vaccine. A second dose of the Pfizer / BioNTech vaccine should not be given to those who have experienced anaphylaxis to the first dose of Pfizer / BioNTech vaccination.

b) Vaccine recipients should be monitored for 15 minutes after vaccination, with a longer observation period when indicated after clinical assessment.

c) A protocol for the management of anaphylaxis and an anaphylaxis pack must always be available whenever the Pfizer / BioNTech vaccine is given. Immediate treatment should include early treatment with 0.5mg intramuscular Adrenaline ( 0.5ml of 1:1000 or 1mg/ml Adrenaline ), with an early call for help and further IM Adrenaline every 5 minutes.
The health professionals overseeing the immunisation service must be trained to recognise an anaphylactic reaction and be familiar with techniques for resuscitation of a patient with anaphylaxis.

The individuals concerned received prompt treatment and are recovering well.

Like all medicines and vaccines, Pfizer / BioNTech vaccine can cause side effects. Most of these are mild and short-term, and not everyone gets them. ( Xagena )

Source: MHRA - The Medicines and Healthcare products Regulatory Agency, 2020

XagenaMedicine2020